363 related articles for article (PubMed ID: 18621530)
21. Synthesis and biological evaluation of pyrazolo[4,3-d]pyrimidine analogues.
Yuan L; Song C; Li C; Li Y; Dong L; Yin S
Eur J Med Chem; 2013 Sep; 67():152-7. PubMed ID: 23851116
[TBL] [Abstract][Full Text] [Related]
22. A new class of small molecule inhibitor of BMP signaling.
Sanvitale CE; Kerr G; Chaikuad A; Ramel MC; Mohedas AH; Reichert S; Wang Y; Triffitt JT; Cuny GD; Yu PB; Hill CS; Bullock AN
PLoS One; 2013; 8(4):e62721. PubMed ID: 23646137
[TBL] [Abstract][Full Text] [Related]
23. Activin A receptor type 1-mediated BMP signaling regulates RANKL-induced osteoclastogenesis via canonical SMAD-signaling pathway.
Omi M; Kaartinen V; Mishina Y
J Biol Chem; 2019 Nov; 294(47):17818-17836. PubMed ID: 31619522
[TBL] [Abstract][Full Text] [Related]
24. Liquid-phase synthesis of combinatorial libraries based on 7-trifluoromethyl-substituted pyrazolo[1,5-a]pyrimidine scaffold.
Dalinger IL; Vatsadse IA; Shevelev SA; Ivachtchenko AV
J Comb Chem; 2005; 7(2):236-45. PubMed ID: 15762751
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
26. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
27. Structure-activity relationships of compounds targeting mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate synthase.
Mao J; Eoh H; He R; Wang Y; Wan B; Franzblau SG; Crick DC; Kozikowski AP
Bioorg Med Chem Lett; 2008 Oct; 18(19):5320-3. PubMed ID: 18783951
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation.
Yoshioka Y; Ono M; Osaki M; Konishi I; Sakaguchi S
Eur J Immunol; 2012 Mar; 42(3):749-59. PubMed ID: 22144105
[TBL] [Abstract][Full Text] [Related]
29. BMP Signaling Regulates Bone Morphogenesis in Zebrafish through Promoting Osteoblast Function as Assessed by Their Nitric Oxide Production.
Windhausen T; Squifflet S; Renn J; Muller M
Molecules; 2015 Apr; 20(5):7586-601. PubMed ID: 25919279
[TBL] [Abstract][Full Text] [Related]
30. Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors.
Yamaguchi-Sasaki T; Tamura Y; Ogata Y; Kawaguchi T; Kurosaka J; Sugaya Y; Iwakiri K; Busujima T; Takahashi R; Ueda-Yonemoto N; Tanigawa E; Abe-Kumasaka T; Sugiyama H; Kanuma K
Chem Pharm Bull (Tokyo); 2020; 68(4):345-362. PubMed ID: 32238652
[TBL] [Abstract][Full Text] [Related]
31. Exploration of Pyrazolo[1,5-a]pyrimidines as Membrane-Bound Pyrophosphatase Inhibitors.
Johansson NG; Dreano L; Vidilaseris K; Khattab A; Liu J; Lasbleiz A; Ribeiro O; Kiriazis A; Boije Af Gennäs G; Meri S; Goldman A; Yli-Kauhaluoma J; Xhaard H
ChemMedChem; 2021 Nov; 16(21):3360-3367. PubMed ID: 34459148
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
Li L; Zhang W; Lin F; Lu X; Chen W; Li X; Zhou X; Su R; Wang L; Zheng Z; Li S
Eur J Med Chem; 2019 Jul; 173():107-116. PubMed ID: 30995566
[TBL] [Abstract][Full Text] [Related]
34. Bone morphogenetic protein type I receptor inhibition induces cleft palate associated with micrognathia and cleft lower lip in mice.
Lai Y; Xie C; Zhang S; Gan G; Wu D; Chen W
Birth Defects Res A Clin Mol Teratol; 2016 Jul; 106(7):612-23. PubMed ID: 27150428
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and antimycobacterial evaluation of various 6-substituted pyrazolo[3,4-d]pyrimidine derivatives.
Trivedi A; Vaghasiya S; Dholariya B; Dodiya D; Shah V
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):893-9. PubMed ID: 21054238
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.
Qiao L; Choi S; Case A; Gainer TG; Seyb K; Glicksman MA; Lo DC; Stein RL; Cuny GD
Bioorg Med Chem Lett; 2009 Nov; 19(21):6122-6. PubMed ID: 19783434
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and properties of sildenafil isostere.
Su Z; Zhang Q; Zhao Q; Liu W; Zhao T; Wang H; Li J; Xu J
Arch Pharm (Weinheim); 2021 Oct; 354(10):e2100145. PubMed ID: 34131943
[TBL] [Abstract][Full Text] [Related]
38. Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.
Chen Y; Bai G; Li Y; Ning Y; Cao S; Zhou J; Ding J; Zhang H; Xie H; Duan W
Bioorg Med Chem; 2021 Oct; 48():116422. PubMed ID: 34583130
[TBL] [Abstract][Full Text] [Related]
39. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
40. New advances in synthesis and clinical aspects of pyrazolo[3,4-d]pyrimidine scaffolds.
Abdellatif KRA; Bakr RB
Bioorg Chem; 2018 Aug; 78():341-357. PubMed ID: 29627655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
